ARCHIVES

FDA News: FDA Approved A Supplemental New Drug Application For Nexavar Tablets (Sorafenib) For The Treatment Of Patients With Locally Recurrent Or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory To Radioactive Iodine Treatment.

This article is from The Cancer Letter archive.

Vol. 39 No. 45 | December 17, 2013

Download PDF Visit The Full Archive

Related Articles

In Brief: Magnuson Subcommittee Increases NCI, NIH Budgets Despite Trimming Labor-HEW Bill By $250 Million

August 23, 1974

NCI Cooperative Group Clinical Trials Approved

April 30, 2010

Surgical Oncologists Certification Asked By SSO Workshop

December 9, 1983

Senate Bill Would Require Clinical Trials To Test Gender, Racial Differences In Therapies

August 10, 1990

Pauling Contends His Applications Included Essentials

April 27, 1979

In Brief: Owens Gives Up Hopkins Hospital Presidency, Resume Full Time Role As Center Director

July 15, 1988